Business
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, May 5, 2022 to
About this update from Aldeyra Therapeutics, Inc.
[{"type":"text","content":" LEXINGTON, Mass.--(BUSINESS WIRE)--\nAldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, May 5, 2022 to report financial results for the quarter ended March 31, 2022 and discuss recent corporate highlights.\n\nThe dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 742862. A live audio webcast of the conference call also will be accessible from the “Investors & Media” section of Aldeyra's website at https://ir.aldeyra.com/.\n\nAfter the live webcast, the event will remain archived on Aldeyra's website for 90 days.\n\nAbout Aldeyra\n\nAldeyra discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220426006340/en/\n\nCorporate Contact:\nJoshua Reed\nAldeyra Therapeutics, Inc.\nTel: 781-761-4904 ext. 218\[email protected]\n\nInvestor & Media Contact:\nScott Solomon\nSharon Merrill Associates, Inc.\nTel: 617-542-5300\[email protected]\n\nSource: Aldeyra Therapeutics, Inc.","length":4592,"tagName":"div"}]